• 1
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 526
  • 2
    Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy. Urology 2007; 69: 7882
  • 3
    Van Der Meijden AP, Sylvester R, Oosterlinck W et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005; 48: 36371
  • 4
    Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 8626
  • 5
    Daniltchenko DI, Riedl CR, Sachs MD et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005; 174: 212933
  • 6
    Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 2008; 53: 113848
  • 7
    Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69: 6759
  • 8
    Zaak D, Karl A, Knuchel R et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005; 96: 21722
  • 9
    D’Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. Eur Urol 2002; 42: 41725
  • 10
    Kriegmair M, Zaak D, Stepp H et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 1999; 36: 38692
  • 11
    Loidl W, Schmidbauer J, Susani M, Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 2005; 47: 3236
  • 12
    Witjes JA, Moonen PM, Van Der Heijden AG. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 2005; 47: 31922
  • 13
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 143548
  • 14
    Tyrkus M, Powell I, Fakr W. Cytogenetic studies of carcinoma in situ of the bladder: prognostic implications. J Urol 1992; 148: 446
  • 15
    Grossman HB. Improving the management of bladder cancer with fluorescence cystoscopy. J Environ Pathol Toxicol Oncol 2007; 26: 1437
  • 16
    Fradet Y, Grossman HB, Gomella L et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 6873
  • 17
    Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155: 1059
  • 18
    Grossman HB, Gomella L, Fradet Y et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178: 627
  • 19
    Jichlinski P, Guillou L, Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer – a multicenter study. J Urol 2003; 170: 2269
  • 20
    Burger M, Zaak D, Stief CG et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 2007; 52: 1427
  • 21
    May F, Treiber U, Hartung R, Schwaibold H. Significance of random bladder biopsies in superficial bladder cancer. Eur Urol 2003; 44: 4750
  • 22
    Van Der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, De Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999; 35: 26771
  • 23
    Swinn MJ, Walker MM, Harbin LJ et al. Biopsy of the red patch at cystoscopy: is it worthwhile? Eur Urol 2004; 45: 4714
  • 24
    Sauter G, Algaba F, Amin M et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In EbleJN, SauterG, EpsteinJL, SesterhennI eds, WHO Classification of Tumors of the Urinary System and Male Genital Organs. Lyon: IARCC Press, 2004: 2934
  • 25
    Garbar C, Mascaux C, Wespes E. Is urinary tract cytology still useful for diagnosis of bladder carcinomas? A large series of 592 bladder washings using a five-category classification of different cytological diagnoses. Cytopathology 2007; 18: 7983